🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

“When Less Is Truly More” Excited to share our work from Med Onc CMC Vellore (Official) published in JCO Global Oncology "Does adding low dose Nivo to NACT ⬆️response rates & survival in stage III non-oncogene-driven NSCLC?" 🔗doi.org/10.1200/GO-24-… Mentor Ashish Singh Key findings👇🧵#LCSM

Impressive spider plots of PD1-VEGF bispecific BNT327/PM8002 plus first line chemo (left) or 2nd line paclitaxel (R) in ext stage small cell lung cancer. Caveat is SCLC is diff in China, 1/3 of pts never smokers, but nevertheless adds to growing PD1-VEGF bispecific dataset #lcsm

#ELCC25 Conclusion of Orchard study to chose DatoDxd 6mg/kg to move forward seems suspect to me. The 4mg/kg dose had much worse prognostic factors, slide below, I don’t think you can really make a comparison between them based on this cohort & 6mg looks worryingly toxic. #lcsm

My #ELCC25 Top 3: 1. #MARIPOSA: meets OS (HR 0.75), but tox burden limits to a subset of pts? Controversial 2. #KRYSTAL7: mPFS 27.7m. Way better than I expected. One to watch 3. #Deescalation trials by Benjamin Besse. Let’s be good oncologists, &good citizens Thanks ESMO - Eur. Oncology

Further to below, recent US report of tempus data on smoking vs non smoking related small cell lung cancer, quite different entities clinical-lung-cancer.com/action/showPdf… #lcsm

Great talks at the NCCP National Lung Cancer Audit, key advances include: - molecular testing (need for molecular KPI) - neoadjuvant therapy (new KPIs needed for this path) - first steps into lung cancer screening via #LungHealthCheck HSE Ireland Department of Health National Screening Service #LCSM

Discover the top oncologists based on views and posts on X leading the Lung Cancer conversations in Q1 2025—powered by LARVOL CLIN. #LARVOL #Oncology #CancerResearch #LungCancer #ClinicalTrials #OncologyInsights | Stephen V Liu, MD | Eric K. Singhi, MD | Hidehito HORINOUCHI | Jarushka Naidoo |

Big news in small cell lung cancer, a disease which historically has had a very poor prognosis. The T cell engager, tarlatamab improves survival vs. 2nd line chemo. Hope is that durable responses will be seen & early phase data were encouraging. #lcsm investors.amgen.com/news-releases/…

Congratulations to Dr. Sarah E. Lochrin Irish fellow and former tumour board Tuesday collaborator and all who received ASCO merit awards!

Set your #ASCO25 alarm clock to Chicago time for Lung Cancer oral presentations on Mon June 2! Honoured to present late breaker 5yr overall survival w neoadj chemo-nivo, alongside colleagues including Jamie Chaft (NeoADAURA) & Charlie Rudin (tarlatamab in SCLC)! #lcsm

Med onc colleagues consider this academic clinical leadership role Cancer Research @UCC in Cork, minutes from the most beautiful coastline in Europe. Excellent academic & clinical colleagues & a competitive salary currently euro 341k/yr for those with 6yrs+ attending/consultant experience

Excited to see these presentations at ASCO25. Both potentially practice affirming/changing

Will 3 cycles of neoadjuvant chemo/ICI give patients a comparable OS boost to periop pembro?!?! How do patients w/ pCR do in the long term? Do they need adjuvant ICI? Can novel neoadjuvant combinations including an ADC ⬆️ pCR? Can’t wait to find out at #ASCO25 #LCSM!

Australia's universal healthcare is crumbling. Can it be saved? bbc.com/news/articles/…

Really delighted and grateful to be elected to a professorial fellowship at Trinity College Dublin Huge gratitude to my colleagues, collaborators and friends who have supported me over the years, but huge 🙏 to Suzie and my family ❤️ Trinity St James's Cancer Institute TTMI - Trinity Translational Medicine Institute School of Medicine

My strongest support for Dr. Tina Cascone MD PhD who has been nominated for the Society for Immunotherapy of Cancer board of directors election! She is a truly outstanding physician scientist, generous collaborator, leader in SITC and great human being! Please vote! sitcancer.org/membership/202…

West Waterford!

First report on TIL therapy resistance in lung cancer! 📰 👉nature.com/articles/s4301… We show subclonal neoantigens are lost on progression; & antigen-specific TIL decay in non-responders. Proud of our team, and thanks to Stand Up To Cancer for funding! Nature Cancer @moffittnews